These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 16118266)

  • 1. Proton pump inhibitor formulary considerations in the acutely ill. Part 1: Pharmacology, pharmacodynamics, and available formulations.
    Devlin JW; Welage LS; Olsen KM
    Ann Pharmacother; 2005 Oct; 39(10):1667-77. PubMed ID: 16118266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton pump inhibitor formulary considerations in the acutely ill. Part 2: Clinical efficacy, safety, and economics.
    Devlin JW; Welage LS; Olsen KM
    Ann Pharmacother; 2005 Nov; 39(11):1844-51. PubMed ID: 16204393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comment: Proton pump inhibitor formulary considerations in the acutely ill. Part 1: pharmacology, pharmacodynamics, and available formulations.
    Conrad SA
    Ann Pharmacother; 2006 May; 40(5):997; author reply 997-8. PubMed ID: 16608907
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment with proton pump inhibitors in acute non-variceal upper gastrointestinal bleeding: a meta-analysis.
    Khuroo MS; Khuroo MS; Farahat KL; Kagevi IE
    J Gastroenterol Hepatol; 2005 Jan; 20(1):11-25. PubMed ID: 15610441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proton pump inhibitors for acid suppression in the intensive care unit: formulary considerations.
    Devlin JW
    Am J Health Syst Pharm; 2005 May; 62(10 Suppl 2):S24-30. PubMed ID: 15905598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy.
    Metz DC; Vakily M; Dixit T; Mulford D
    Aliment Pharmacol Ther; 2009 May; 29(9):928-37. PubMed ID: 19298580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness and budget impact of intravenous versus oral proton pump inhibitors in peptic ulcer hemorrhage.
    Spiegel BM; Dulai GS; Lim BS; Mann N; Kanwal F; Gralnek IM
    Clin Gastroenterol Hepatol; 2006 Aug; 4(8):988-997. PubMed ID: 16844422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescribing proton pump inhibitors for initial treatment of acid-related gastrointestinal diseases in a managed care population.
    Chan J; Hui RL; Szpakowski JL
    Am J Manag Care; 2004 Jul; 10(7 Pt 1):433-41. PubMed ID: 15298365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a metaanalysis.
    Cremonini F; Wise J; Moayyedi P; Talley NJ
    Am J Gastroenterol; 2005 Jun; 100(6):1226-32. PubMed ID: 15929749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of diclofenac or other non-steroidal anti-inflammatory drugs (NSAIDs) and diclofenac or other NSAIDs in combination with proton pump inhibitors (PPI) on hospitalisation due to peptic ulcer disease.
    Höer A; Gothe H; Schiffhorst G; Sterzel A; Grass U; Häussler B
    Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):854-8. PubMed ID: 17323403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: acid-related disease--what are the unmet clinical needs?
    Katz PO; Scheiman JM; Barkun AN
    Aliment Pharmacol Ther; 2006 Jun; 23 Suppl 2():9-22. PubMed ID: 16700899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stress-induced ulcer bleeding in critically ill patients.
    Ali T; Harty RF
    Gastroenterol Clin North Am; 2009 Jun; 38(2):245-65. PubMed ID: 19446257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children.
    Canani RB; Cirillo P; Roggero P; Romano C; Malamisura B; Terrin G; Passariello A; Manguso F; Morelli L; Guarino A;
    Pediatrics; 2006 May; 117(5):e817-20. PubMed ID: 16651285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intragastric pH with oral vs intravenous bolus plus infusion proton-pump inhibitor therapy in patients with bleeding ulcers.
    Laine L; Shah A; Bemanian S
    Gastroenterology; 2008 Jun; 134(7):1836-41. PubMed ID: 18423628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton pump inhibitor utilization patterns in infants.
    Barron JJ; Tan H; Spalding J; Bakst AW; Singer J
    J Pediatr Gastroenterol Nutr; 2007 Oct; 45(4):421-7. PubMed ID: 18030207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.
    Hur C; Chan AT; Tramontano AC; Gazelle GS
    Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proton pump inhibitors for the prevention of stress-related mucosal disease in critically-ill patients: a meta-analysis.
    Pongprasobchai S; Kridkratoke S; Nopmaneejumruslers C
    J Med Assoc Thai; 2009 May; 92(5):632-7. PubMed ID: 19459523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes associated with concomitant use of atazanavir and proton pump inhibitors.
    Sahloff EG; Duggan JM
    Ann Pharmacother; 2006 Oct; 40(10):1731-6. PubMed ID: 16968825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada.
    Rahme E; Barkun A; Nedjar H; Gaugris S; Watson D
    Am J Gastroenterol; 2008 Apr; 103(4):872-82. PubMed ID: 18371130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic properties of proton pump inhibitors.
    Welage LS
    Pharmacotherapy; 2003 Oct; 23(10 Pt 2):74S-80S. PubMed ID: 14587961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.